Glyceryl behenate-based solid lipid nanoparticles as a carrier of haloperidol for nose to brain delivery: formulation development, in-vitro, and in-vivo evaluation

This study was aimed to develop the haloperidol (HPL) loaded solid lipid nanoparticles (SLNs) for brain targeting through intranasal route. SLNs were fabricated by emulsification diffusion technique using glyceryl behenate as and tween 80 a surfactant. evaluated particle size, zeta potential, structure, entrapment efficiency, state characterization differential scanning calorimetry (DSC), in-vitro release. In-vivo biological evaluation performed on albino Wistar rats determination of pharmacokinetic well parameters. Particle PDI, efficiency optimized formulation (HPL-SLNs 6) found be 103±09 nm, 0.190±0.029, -23.5±1.07 mV, 79.46±1.97% respectively. In-vitro drug release studies exhibited that 87.21± 3.63% entrapped released from within 24 h. DSC curves confirmed during in SLNs, solubilized matrix converted into amorphous form. Enhanced HPL observed HPL-SLNs compared HPL-Sol when administered intranasally. The value AUC 0-? i.n. nearly 2.7 times higher than i.v., whereas 3.66 superior Stability revealed remains unchanged stored at 4±2 °C (refrigerator) 25±2 /60 ±5% RH up six months. Finally, it could concluded SLN is suitable carrier with enhanced i.n administration, HPL-Sol, i.v.